Bellicum Pharmaceuticals Inc (BLCM) Return on Assets ROA from the third quarter of 2023 to third quarter of 2022 and for the year 2023, Average High and Low, Fundamental Ratios from Sep 30 2023 to Sep 30 2022 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Bellicum Pharmaceuticals Inc   (BLCM)


Bellicum Pharmaceuticals Inc 's ROA from the third quarter of 2023 to the third quarter of 2022 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Bellicum Pharmaceuticals Inc 's ROA in the third quarter of 2023?
Bellicum Pharmaceuticals Inc achieved a return on average assets (ROA) of 18.3 % in its third quarter of 2023, this is above BLCM's average return on assets of -43.13%.
Bellicum Pharmaceuticals Inc assets over the 12 months ending in its third quarter of 2023 are valued at $14 million

ROA has improved compared to -19.02% in the second quarter of 2023, due to net income growth.

However, within the Healthcare sector 41 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2023 quarter, so far to 281, from total ROA ranking in the second quarter of 2023 at 3892.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter		 (Sep 30 2022)
III. Quarter
Y / Y Total Assets Change -78.09 % -76.14 % -60.26 % -51.52 % 39.82 %
Y / Y Net Income Change - - - 525.8 % -
Net Income (TTM) in million 3 -4 -1 0 -16
Return On Assets (TTM) 18.3 % -19.02 % -1.86 % -0.01 % -39.33 %
BLCM's Total Ranking # 281 # 3892 # 3214 # 3359 # 4673
Total Assets (TTM) in million 7 9 17 24 31
Seq. Total Assets Change -21.53 % -49.4 % -27.55 % -23.85 % -14.54 %
Seq. Net Income Change - - - - -

BLCM's 5 Years Annual ROA >> Back to BLCM Management Effectiveness >> Compare BLCM ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 20
Sector # 42
Overall # 273

Return On Assets Statistics
High Average Low
61.35 %
-43.13 %
-100.41 %
(Sep 30 2021)  





Financial Statements
Bellicum Pharmaceuticals Inc 's Assets $ 7 million BLCM's Balance sheet
Bellicum Pharmaceuticals Inc 's Income $ -1 million Quarterly BLCM's Income Statement
BLCM's Income by Division See BLCM's Income by Division



Annual Return On Assets (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021		 (Dec 31 2020)
FY 2020		 (Dec 31 2019)
FY 2019		 (Dec 31 2018)
FY 2018
Y / Y Total Assets Change -51.52 % 21.09 % -65.09 % -4.32 % -10.35 %
Total Assets in million 24 49 41 116 122
Y / Y Net Income Change - - - - -
Net Income in million 0 -10 -8 -112 -98
Annual Return On Assets -0.01 % -19.75 % -19.03 % -96.75 % -80.69 %

BLCM's 5 Years Annual ROA >> Back to BLCM Management Effectiveness >> Compare BLCM ROA to its Competitors



More Return On Assets Ratios
BLCM's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
BLCM's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for BLCM's Competitors
Subscribers only: Roa for Bellicum Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for BLCM's Customers

You may also want to know
BLCM's Roi BLCM's Inventory Turnover Ratio BLCM's Growth Rates BLCM's Dividend Comparisons
BLCM's Profitability Ratios BLCM's Asset Turnover Ratio BLCM's Dividend Growth
BLCM's Roe BLCM's Valuation Ratios BLCM's Financial Strength Ratios BLCM's Dividend Payout Ratio



Companies with similar Return On Assets at Sep 30 2023, within Healthcare Sector ROA
Molecular Templates Inc   40.96 %
Northview Acquisition Corp  37.76 %
Elite Pharmaceuticals Inc   36.88 %
Entera Bio Ltd   35.29 %
Star Equity Holdings Inc   34.97 %
Zymeworks Inc   34.09 %
Lite Strategy Inc   32.68 %
One World Products Inc   29.91 %
Tao Synergies Inc   28.70 %
Idexx Laboratories Inc  28.59 %
Avalo Therapeutics Inc   27.43 %
Semler Scientific inc   27.21 %
Shockwave Medical Inc   26.44 %
Enzo Biochem Inc  25.81 %
Denali Therapeutics Inc   24.40 %
Mettler toledo International Inc   23.37 %
Nrc Health  22.18 %
Arcturus Therapeutics Holdings Inc   21.96 %
Harmony Biosciences Holdings inc   20.60 %
Iradimed Corporation  19.79 %
Medpace Holdings Inc   19.37 %
Voyager Therapeutics Inc   18.92 %
Waters Corporation  18.85 %
Johnson and Johnson  18.69 %
Bellicum Pharmaceuticals Inc   18.30 %
Point Biopharma Global Inc   18.28 %
Tenax Therapeutics Inc   18.00 %
Vertex Pharmaceuticals Inc  17.52 %
Vaso Corporation  16.61 %
Chemed Corporation  16.47 %

Date modified: 2026-09-18T13:11:05+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.